Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT04428788
Last Updated: 2025-12-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
131 participants
INTERVENTIONAL
2020-06-22
2025-10-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Administration of CC-94676, CC1083611, and CC1083610
CC-94676
Specified dose on specified days
CC1083611
Specified dose on specified days
CC1083610
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CC-94676
Specified dose on specified days
CC1083611
Specified dose on specified days
CC1083610
Specified dose on specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC)
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
Exclusion Criteria
* Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 1 year prior to the first dose of IP
* Clinically significant venous thromboembolism within 3 months prior to the first dose of IP
* Any significant medical condition, such as uncontrolled infection, laboratory abnormality, or psychiatric illness
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celgene
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 116
Stanford, California, United States
Local Institution - 122
Washington D.C., District of Columbia, United States
Local Institution - 103
Sarasota, Florida, United States
Local Institution - 121
Thomasville, Georgia, United States
Local Institution - 108
Baltimore, Maryland, United States
Local Institution - 104
Boston, Massachusetts, United States
Local Institution - 117
Ann Arbor, Michigan, United States
Local Institution - 102
Grand Rapids, Michigan, United States
Local Institution - 112
New York, New York, United States
Local Institution - 109
New York, New York, United States
Local Institution - 105
New York, New York, United States
Local Institution - 106
Durham, North Carolina, United States
Local Institution - 120
Allentown, Pennsylvania, United States
Local Institution - 113
Philadelphia, Pennsylvania, United States
Local Institution - 107
Dallas, Texas, United States
Local Institution - 119
Houston, Texas, United States
Local Institution - 101
San Antonio, Texas, United States
Local Institution - 115
Seattle, Washington, United States
Local Institution - 111
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1251-9174
Identifier Type: OTHER
Identifier Source: secondary_id
CC-94676-PCA-001
Identifier Type: -
Identifier Source: org_study_id